87 results about "Andrographolide derivatives" patented technology

The invention belongs to the technical field of medicines, discloses applications of andrographolide derivatives in preparation of medicines preventing and treating hepatic fibrosis, and relates to 15-benzylidene-14-deoxy-11,12-dehydroandrographolide derivatives and 3,19 esterified compounds thereof. Experiments prove that the compounds significantly inhibit human hepatic stellate cell LX-2 metastasis and activation, significantly reduce the fibrosis level of hepatic tissues of rats affected with hepatic fibrosis, reduce contents of extracellular matrix protein (ECM) related components, significantly reduce the level of immune inflammation correlation factors of rats affected with hepatic fibrosis, effectively inhibit immuno-inflammatory responses, inhibit hepatic stellate cell activation in hepatic tissues, and promote collagen degradation. The compounds are used as active components for preparing the anti-hepatic fibrosis medicines, and are efficient and low in toxicity, thus providing a novel medicine route for hepatic fibrosis treatment and prevention, and expanding the optional range of clinical medicine application. The compounds and the applications have good development prospects.

The invention belongs to the technical field of medicine, discloses the application of andrographolide derivative in preparation antineoplastic agents, and relates to 15-benzyl subunit -14-deoxy-11,12-dehydrogenation andrographolide derivative and 3,19 esters thereof. The experience shows that the chemical compounds have the remarkable effects of restraining cancer cell cloning and forming and resisting migration of cancer cell and human vascular endothelial; and the chemical compounds show stronger effects of restraining tumor growth, antimetastasis and antiangiogenic in a mice transplanting tumour animal model. The chemical compounds are used as activity components for preparing antineoplastic agents, have the advantages of high efficient and low toxicity. the invention provides a new drug way for curing and preventing transfer of the tumour, expands selection range of clinical pharmacy, and is significant to taking full advantage of plant resources of the common andrographis herb.

The invention belongs to the technical field of medicinal chemistry, and discloses application of andrographolide C15 substituted series derivatives to the preparation of a medicine for resisting hepatitis B. HepG2.2.15 cells are used for detecting the secretion amount of hepatitis B surface antigen (HBsAg) in culture solution supernatant, a large number of andrographolide derivative compounds are screened, and compounds which have high hepatitis B virus (HBV) resistance are optimally selected and have a structure shown in a general formula 1; and the compounds have high HBV-resistant activity, high efficiency and low toxicity and are taken as active ingredients to be used for preparing a medicine for resisting viral hepatitis B, and a new medicine is provided for treating hepatitis, so that the selectable range of clinical medicines is expanded.

We describe for the first time that andrographolide dirivatives such as DDAG effectively reduced OVA-induced inflammatory cell recruitment into BAL fluid, IL-4, IL-5, IL-13 and eotaxin production, serum IgE synthesis, pulmonary eosinophilia, mucus hypersecretion and AHR in a mouse asthma model potentially via inhibition of NF-kappa B activity. Moreover, low dose of DDAG and glucocorticoid combination treatment synergistically attenuate inflammation in mouse asthma model. These findings support a therapeutic value for DDAG in the treatment of asthma.

The present invention relates to novel derivatives of Andrographolide, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, and their pharmaceutically acceptable solvates. The novel derivatives of Andrographolide have the general formula (I)The andrographolide derivatives represented by general formula (I) are useful for treating cancer, HSV, HIV, psoriasis, restonosis, atherosclerosis, other cardiovascular disorders, and can be used as antiviral, antimalarial, antibacterial, hepatoprotective, and immunomodulating agents and for treatment of other metabolic disorders.

The invention discloses a compound and medical acceptable salt with general formula (I) and making method and their drug agent, which possesses better COX-2 expressive inhibiting and TNF-alpha inhibiting and IL-6 inhibiting action.